Aerpio Therapeutics Closes $27M Series A Financing

Aerpio Therapeutics, a Cincinnati, OH-based clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, has closed a $27m Series A financing.

The round was led by Novartis BioVentures, with participation from Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and AgeChem Venture Fund.

The company intends to use the funding for ongoing development of its pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema (DME).

Led by Dr. Joseph Garner, President and CEO, Aerpio was created in a spin‐out transaction from Akebia Therapeutics in December 2011.



Join the discussion